Subscribe

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology - FDA Approvals, Multiple Myeloma, Conference Highlights ASCO

On July 9, 2021, the FDA accelerated the approval of a new indication for daratumumab and hyaluronidase-fihj (Darzalex Faspro; Janssen Biotech), in combination with pomalidomide (Pomalyst; Bristol Myers Squibb) and dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous line of therapy, including lenalidomide (Revlimid) or a proteasome inhibitor.

Daratumumab and hyaluronidase, as well as pomalidomide, are each already approved for the treatment of patients with multiple myeloma, alone or in combination with other drugs.

This new indication was based on the results of the APOLLO study, an open-label, active-controlled clinical trial of 304 patients who were randomized in a 1:1 ratio to daratumumab and hyaluronidase plus pomalidomide and dexamethasone or to pomalidomide and dexamethasone alone.

“With this approval, we are now able to combine pomalidomide and dexamethasone with a daratumumab subcutaneous option that can be administered in minutes rather than the hours needed for intravenous administration,” said Meletios A. Dimopoulos, MD, Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece, and the study’s principal investigator.

The primary end point was progression-free survival (PFS). The median PFS was 12.4 months in the daratumumab and hyaluronidase plus pomalidomide and dexamethasone arm versus 6.9 months with pomalidomide and dexamethasone alone (hazard ratio, 0.63; 95% CI, 0.47-0.85; P = .0018), a 37% risk reduction for disease progression or death with the 3-drug versus the 2-drug combination.

The most common (≥20%) adverse reactions with the 3-drug combination were fatigue, pneumonia, upper respiratory tract infection, and diarrhea.

Related Items
Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer
Web Exclusives published on August 9, 2021 in FDA Approvals
ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care
Wayne Kuznar
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on August 9, 2021 in Disparities in Cancer Care, Conference Highlights ASCO
Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer
Web Exclusives published on August 9, 2021 in FDA Approvals
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on August 9, 2021 in Conference Highlights ASCO, Lung Cancer
Trodelvy Receives New Indication for Advanced Urothelial Cancer
Web Exclusives published on August 9, 2021 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.